Ramucirumab plus paclitaxel as second-line treatment in patients with advanced gastric or gastroesophageal junction adenocarcinoma: a nationwide real-world outcomes in Korea study (KCSG-ST19-16).
Hye Sook HanBum Jun KimHee-Jung JeeMin-Hee RyuSe Hoon ParkSun Young RhaJong Gwang KimWoo Kyun BaeKeun-Wook LeeDo-Youn OhIn-Ho KimSun Jin SymSo Yeon OhHyeong Su KimJi-Hye ByunDong Sook KimYoung Ju SuhHyonggin AnDae Young ZangPublished in: Therapeutic advances in medical oncology (2021)
Our large-scale, nationwide, real-world data analysis of an unselected real-world population adds evidence for the efficacy and safety of second-line ramucirumab plus paclitaxel in patients with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.
Keyphrases
- locally advanced
- squamous cell carcinoma
- rectal cancer
- neoadjuvant chemotherapy
- phase ii study
- radiation therapy
- small cell lung cancer
- cross sectional
- electronic health record
- type diabetes
- skeletal muscle
- machine learning
- insulin resistance
- metabolic syndrome
- artificial intelligence
- combination therapy
- weight loss